Lin Sun, Yincang Wang, Jiazhe Du, Xilin Xu, Zhang Xiaofeng
Second Affiliated Hospital of Heilongjiang, University Of Chinese Medicine, Harbin, China.
The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Front Pharmacol. 2024 Dec 12;15:1486646. doi: 10.3389/fphar.2024.1486646. eCollection 2024.
Osteoporosis (OP) stands as the most prevalent systemic skeletal condition associated with aging. The current clinical management of OP predominantly depends on anti-resorptive and anabolic agents. Nevertheless, prolonged use of some of these medications has been observed to reduce efficacy and elevate adverse effects. Given the necessity for sustained or even lifelong treatment of OP, the identification of drugs that are not only effective but also safe and cost-efficient is of utmost significance. As disease treatment paradigms continue to evolve and recent advancements in OP research come to light, certain plant-derived compounds have emerged, presenting notable benefits in the management of OP. This review primarily explores the pharmacological properties of apigenin and elucidates its therapeutic mechanisms in the context of OP. The insights provided herein aspire to offer a foundation for the judicious use of apigenin in forthcoming research, particularly within the scope of OP.
骨质疏松症(OP)是与衰老相关的最常见的全身性骨骼疾病。目前OP的临床管理主要依赖于抗吸收和促合成药物。然而,已观察到长期使用其中一些药物会降低疗效并增加不良反应。鉴于OP需要持续甚至终身治疗,识别不仅有效而且安全且具有成本效益的药物至关重要。随着疾病治疗模式不断演变以及OP研究的最新进展得以揭示,某些植物来源的化合物已崭露头角,在OP管理方面呈现出显著益处。本综述主要探讨芹菜素的药理特性,并阐明其在OP背景下的治疗机制。本文提供的见解旨在为芹菜素在未来研究中的合理使用提供基础,尤其是在OP范围内。